We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pelago Bioscience Takes Strides Towards in vitro Diagnostic Application of CETSA®
Product News

Pelago Bioscience Takes Strides Towards in vitro Diagnostic Application of CETSA®

Pelago Bioscience Takes Strides Towards in vitro Diagnostic Application of CETSA®
Product News

Pelago Bioscience Takes Strides Towards in vitro Diagnostic Application of CETSA®


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Pelago Bioscience Takes Strides Towards in vitro Diagnostic Application of CETSA®"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pelago Bioscience has been awarded a 3.6M SEK Swelife grant to use its patented CETSA® technique to identify new oncology biomarkers to aid the treatment of childhood leukaemia.

Current treatment regimens are based on medication developed for adult cancers and there is little information to guide the appropriate regime in children, resulting in issues with reduced clinical efficacy and toxicity.

Pelago’s CETSA MS format can be used to profile the effect of a drug on up to 6000 proteins. This will be applied to patient blood samples and will identify ‘unique fingerprints’ associated with best clinical outcomes for each of 6 commonly used cancer drugs. Initially this profiling will be offered as a service but further studies will identify the key components of the finger print and reduce the number of proteins that need to be assessed. This will enable the development of a routine diagnostic assay.

CEO of Pelago Bioscience, Dr. Michael Dabrowski comments:

“Worldwide there are around 352,000 people diagnosed with a type of leukaemia each year, and it is the most common cancer in children and teens. Working in this area, and using our CETSA® technique to help identify new oncology biomarkers to support the treatment of children with leukaemia, has been hugely helped by the injection of grant funding from Swelife.”
Advertisement